Clinical Trials Logo
NCT number NCT00230191
Study type Interventional
Source RxKinetix
Status Completed
Phase Phase 2
Start date January 2003
Completion date December 2005

Clinical Trial Summary

The primary objective of the study is to assess the effect of RK-0202 versus placebo on the incidence and severity of oral mucositis in subjects receiving radiation therapy for head and neck cancer. Concurrent chemotherapy is not allowed in the study.

Clinical Trial Description

Approximately 42,000 new cases of head and neck squamous cell carcinoma occur annually in the United States. Radiotherapy (“RT”) plays a significant role in the management of head and neck cancer. The most common and clinically significant toxicities arising from head and neck radiation therapy are acute mucositis and acute and chronic xerostomia (dry mouth or salivary gland changes). In subjects receiving RT for cancers of the oral cavity or oropharynx the incidence of acute mucositis can exceed 90%. The painful ulceration of the oral mucosa produced by the radiation often leads to the requirement for narcotics to control pain, inability to eat, dehydration, the need for parenteral nutrition and, sometimes, breaks in RT. In addition to its symptomatic cost, the presence of mucositis has been associated with a number of other adverse outcomes including higher costs and more frequent hospitalizations.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention

Related Conditions & MeSH terms

See also
  Status Clinical Trial Phase
Active, not recruiting NCT02572869 - Functional and Aesthetic Outcomes After Mandible Reconstruction With Fibula Osteomyocutaneous Free Flaps N/A
Recruiting NCT02823574 - Study of Nivolumab in Combination With Ipilimumab Versus Nivolumab in Combination With Ipilimumab Placebo in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Phase 2
Withdrawn NCT03238638 - A Study of Epacadostat + Pembrolizumab in Head and Neck Cancer Patients, Who Failed Prior PD-1/PD-L1 Therapy Phase 2
Not yet recruiting NCT03266276 - Assessing Impact of CCO's PSO & PC Pathway in Ambulatory HNC Clinics N/A
Not yet recruiting NCT03265873 - Contribution of the ENT (Ear, Nose, and Throat) Surgeon's Clinical Evaluation to the Contouring of Target Volumes and Organs Eligible for Radiotherapy in Head and Neck Cancers N/A
Recruiting NCT03302676 - The Use of Chewing Gum for Xerostomia and Hyposalivation After Radiotherapy for Oral and Oropharyngeal Tumors Phase 3
Not yet recruiting NCT02875795 - Carcinologic Speech Severity Index N/A
Recruiting NCT02546895 - Prospective Registration of Head and Neck Cancer N/A
Recruiting NCT02526017 - Study of FPA008 in Combination With Nivolumab in Patients With Selected Advanced Cancers Phase 1
Recruiting NCT02308072 - Phase I Study of Olaparib Combined With Cisplatin-based Chemoradiotherapy to Treat Locally Advanced Head and Neck Cancer Phase 1
Recruiting NCT02554968 - Reliability and Validity of Patient Reported Outcome Measures in Head and Neck Cancer N/A
Recruiting NCT02017509 - Immunoscore in Rectal Cancer N/A
Recruiting NCT02921984 - Concurrent Chemotherapy Based on Genetic Testing in Patients With High-Risk Salivary Gland Tumors Phase 1
Recruiting NCT02489084 - Predictive Models for Radiation-induced Side Effects in Head and Neck Cancer Based on Single Nucleotide Polymorphisms (SNP) N/A
Active, not recruiting NCT01895829 - Ferumoxytol - Iron Oxide Nanoparticle Magnetic Resonance Dynamic Contrast Enhanced MRI Early Phase 1
Completed NCT02038114 - The Impact of a Patient Education Intervention for Ambulatory Oncology Patients N/A
Completed NCT01955239 - Parotid-gland Stem-cell Sparing Intensity-modulated Radiotherapy N/A
Completed NCT01952821 - Validity and Reliability of Outcome Measures in Patients With Cancer of the Head and Neck N/A
Recruiting NCT01936376 - A Prospective Observational Study to Evaluate Acute Kidney Injury Biomarkers In Patients Receiving First Cycle of Cisplatin Chemotherapy for Head and Neck Cancers N/A
Withdrawn NCT01506427 - A Study of [F-18]HX4 (PET Imaging)Evaluated in Head and Neck Cancer Patients Phase 1/Phase 2